Yeda Research and Develpment & Co. Ltd

University of Washington

The Weizmann Institute of Science

Rony Seger

Dana Chuderland

Galia Maik-Rachline

Alexander Plotnikov

Eldar Zehorai

Yardena R Samuels

Karen Flores

Ehud Wainstein

Edwin G Krebs

Natalie G Ahn

Dalia Seger

Rand Arafeh

An article of manufacture is disclosed which comprises: Uses thereof are also disclosed.

Combination therapy for the treatment of cancer

An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.

Use of inhibitory peptides for the treatment of inflammatory diseases

An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGXPXQED (SEQ ID NO: 4), wherein Xand Xare any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.

ERK-derived peptides and uses thereof

Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.

Nuclear targeting sequences

The present invention provides anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising at least one altered phosphorylation site, polynucleotides encoding same and uses thereof. Particularly, the present invention provides variants of human PEDF comprising at least one amino acid substitution at serine residues (24), (114), and (227). The PEDF variants are potent anti-angiogenic factors, and thus useful in treating diseases or disorders associated with neovascularization.

Variants of pigment epithelium derived factor and uses thereof

The present invention relates to anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising a plurality of altered phosphorylation sites, polynucleotides encoding same and uses thereof. In particular, the PEDF variants of the present invention provide superior anti-angiogenic activity and high neurotrophic activity and are useful in treating diseases associated with neovascularization and with neurodegenerative conditions.

An isolated nucleic acid molecule which hybridizes under stringent conditions with the nucleic acid shown in SEQ ID NO:32 or its complement or the nucleic acid shown in SEQ ID NO:34 or its complement, and which encodes mitogen activated protein kinase kinase protein.

Growing community of inventors

Yavne, Israel

Rony Seger